PREFACE

\n
1. \n

   INTRODUCTION; Hellmann, K.\n1.1 Overview of the development of razoxane and dexrazoxane

   \n
\n
2. \n

   RAZOXANE\n2.1 Preclinical data - in vitro and in vivo; Hellmann, K.\n2.2 Modes of action, a brief summary; Rhomberg, W.\n2.3 Clinical studies of malignant tumors; Rhomberg, W.\n2.3.1 Razoxane as cytotoxic or cytostatic agent\n2.3.1.1 Leukaemias and lymphomas\n2.3.1.2 Solid tumors, single agent\n2.3.1.3 Solid tumors, multiagent therapy\n2.3.1.4 Adjuvant use of razoxane\n2.3.2 Razoxane as radiosensitizer\n2.3.2.1 Soft tissue- and osteosarcomas, chordomas\n2.3.2.2 Gastro-intestinal malignancies\n2.3.2.3 Lung cancer\n2.3.2.4 Other solid tumors\n2.3.3 Antimetastatic efficacy\n2.3.3.1 Preclinical evidence; Rhomberg, W.\n2.3.3.2 Metastasis and the entry of tumor cells into; the vasculature - prevention by razoxane; Hellmann, K.\n2.3.3.3 Clinical evidence; Rhomberg, W.\n2.3.4 Razoxane - a cytorallentaric drug; Hellmann, K.\n2.3.5 Toxicity; Rhomberg, W.\n2.4 Studies in non-malignant diseases\n2.4.1 Psoriasis and psoriatric arthropathy; Rhomberg, W.\n2.4.2 Crohn s disease and ulcerative colitis; Rhomberg, W.

   \n
\n
3. \n

   DEXRAZOXANE\n3.1 Preface\n3.2 The pharmacology of dexrazoxane; Hasinoff, B.B.\n3.3 Toxicology and pharmacokinetics; Hellmann, K.\n3.4 Identification of dexrazoxane as a cardioprotector; Herman, E.\n3.5 Clinical considerations\n3.5.1 Dexrazoxane as antitumour agent; Rhomberg, W.\n3.5.2 Protection against anthracyclin-induced cardiotoxicity:\n3.5.2.1 Two pivotal clinical studies. A report including pharmacology and safety issues; Rubens, R.\n3.5.2.2 Comments on study 88001 and 88006; Hellmann, K.\n3.5.2.3 Clinical studies on cardioprotection - an update; Jones, R.\n3.5.3 Non-cardioprotective efficacy; Langer, S.W. 3.5.4 Neurodegenerative diseases; Greig, N.

   \n
\n
4. \n

   SUMMARY and OUTLOOK; Hellmann, K. and Rhomberg, W.

   \n
\n